Achieving DSC Certifications With Certified Nurse Specialists

Article

Improving patient care may be possible for institutions achieving Disease-Specific Care certifications with certified nurse specialists at the helm.

According to a presentation at the Oncology Nursing Society’s 46th Annual Congress, improving care for patients with cancer and elevating the role of clinical nurse specialists may be achieved with a Disease-Specific Care (DSC) certification from The Joint Commission.

“Disease-specific care certification focuses [on providing] a framework for continuous, reliable care and gives proof your program meets standards and verifies improvement activity,” said Kathy Burns, MS, APRN-CNS, AGCNS-BC, of The Ohio State’s James Cancer Hospital, which is one of only 3 hospitals in the United States to receive DSC certification for acute leukemia. “Basically, your program is doing what you are saying it’s doing. [It] provides accountability, decreases undesirable variations in care, advances patient outcomes, endorses cultural excellence, [and] provides the community with confidence that the program is providing the quality of care that it is marketing and delivering objectives of the certification [that] are a lasting commitment to clinical excellence for all of us,” Burns said.

Burns is also 1 of more than 72,000 clinical nurse specialists nationwide – a role that she says is vital in the healthcare arena.

“We drive practice change in the organization. [We] advocate to improve patient outcomes and mentor evidence-based practice projects, which I have to say is one of my favorites. We are required to take a course on [evidence-based practices] and then we are required to maintain those competencies. We collaborate on complex patient care issues with multidisciplinary teams throughout the system [and] promote standards on patient care and safety,” she said.

Clinical nurse specialists can also help their institutions achieve a DSC certification by recommending and implementing strategies to improve care and meet disease-specific indicators like:

  • Defining strategies to improve quality
  • Developing policies, procedures, results of tracers, and mock surveys to improve safety
  • Ensuring compliance with clinical practice and evidenced-based care

“Certification programs must demonstrate a systematic approach to care delivery and analysis,” Burns said. “Being at the table, we can help define strategies to improve quality.”

Reference

Burns K, Brown S. Disease Line Clinical Nurse Specialist: The Journey to Obtaining Disease-Specific Care Certification from The Joint Commission. Presented at: The Oncology Nursing Society 46th Annual Congress. April 20, 22, 27, and 29, 2021. Virtual

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content